Comparable outcomes with first-line azacitidine, decitabine in geriatric AML patients

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Jun 14 / Springer Healthcare

Comparable outcomes with first-line azacitidine, decitabine in geriatric AML patients

Yale University and Yale Cancer Center, New Haven, Connecticut, USA

Haematology EHA-2020

Description

Amer Zeidan reports on their analysis of ASTRAL-1 trial data indicating that both azacitidine and decitabine are valid options for geriatric patients with treatment-naïve acute myeloid leukaemia.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.